An Open Prospective Randomized Clinical Study of the Effectiveness, Tolerability and Safety of a Single Intraperitoneal Use of the Drug " Prospidelong, Powder for the Preparation of a Gel for Topical Use, 1000 mg in Vials, Package No. 1 " in Patients With Disseminated Gastric Cancer, Phase I-II

Conditions: Gastric Cancer With Peritoneal Dissemination Interventions: Drug: Prospidelong; Procedure: chemotherapy Sponsors: Research Institute for Physical Chemical Problems of the Belarusian State University; The state institution N. N. Alexandrov National Cancer Centre of Belarus; Unitary Enterprise UNITEHPROM BSU Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials